import React from 'react';

export let chapter_seven = {
    short_title: "Chapter 7",
    long_title: "HIV Related Infections",
    subsections: [{
      short_title: "Section 1",
      long_title: "General Guidelines",
      content:
        <span>
          <h2>General Guidelines</h2>
          <p>These guidelines aim to encourage a consistent clinical management approach and draw a balance between possible interventions and available resources. Further information is available in the Guidelines for Antiretroviral Therapy in Zimbabwe. Always refer to the latest edition of these guidelines.</p>
        </span>
    },
    {
      short_title: "Section 2",
      long_title: "Clinical Presentation",
      content:
        <span>
          <h2>Clinical Presentation</h2>
          <p>Clinical presentation in HIV infection varies greatly, from asymptomatic infection in a normal, fit individual to life threatening conditions. The majority of infected persons remain healthy for a varying period, often many years, but may transmit the virus to others during unprotected sex.</p>
        </span>
    },
    {
      short_title: "Section 3",
      long_title: "General Notes",
      content:
        <span>
          <h2>General Notes</h2>
          <p>All patients should be dcptrial HIV counselling and testing services (PITC). A documented proof of a positive HIV test result should be availed before a patient is enrolled into the Chronic HIV Care program. .</p>
          <p>For notes on the management of HIV infection and related conditions in children, see also “Paediatric Infections”.</p>
          <p>The goal is to provide the earliest possible diagnosis of HIV infection, diagnose opportunistic infections (OIs) promptly and implement therapeutic measures that will extend and improve the quality of life. Please refer to the Guidelines for Antiretroviral Therapy in Zimbabwe for more detail about how to deal with OIs and how to use the ARVs. Most early problems can be adequately and effectively treated so that the HIV infected persons continue to lead a normal and productive life. A continuum of care should be provided from the nearest possible facility to the home or workplace.</p>
          <p>If a patient dcptrial at the primary care level (“C level”) or district hospital (“B level”), follow EDLIZ as far as possible,
          then refer to the next level. Keep referrals to a minimum and only where essential for investigations requiring specialised facilities and specialist advice. Check where your nearest OI/ART Clinic is.</p>
          <p>The following are fundamental to the management of HIV related illness, but cannot be covered fully here (Refer to the national guidelines):</p>
          <ul>
            <li> counselling: pre-testing, post-test, crisis/support;</li>
            <li> health for prevention of further transmission of HIV, positive living; </li>
            <li> Maintenance of good nutrition, vitamin and mineral supplements <strong>.</strong>
            </li>
            <li> Prevention, diagnosis and treatment of OIs</li>
            <li> Use of antiretroviral medicines</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 4",
      long_title: "Cotrimoxazole Prophylaxis",
      content:
        <span>
          <h2>Cotrimoxazole Prophylaxis</h2>
          <p>Cotrimoxazole has been shown to prolong life and reduce hospital admissions in those with symptomatic HIV or AIDS.</p>
          <p>Cotrimoxazole prophylaxis should be given to the following:</p>
          <ul>
            <li>All patients with WHO clinical stages 2, 3, and 4 disease</li>
            <li>All patients with CD4 counts equal or less than 350 cells/mm <sup>3</sup>
            </li>
            <li>Pregnant women with CD4 counts equal or less than 350 cells/mm <sup>3</sup>
            </li>
            <li>All children born to HIV-positive mothers from six weeks of age until they are tested and confirmed to be HIV negative</li>
            <li>Cotrimoxazole prophylaxis should be started <em>as soon as any of the above conditions are suspected</em>; this should be done at every entry point and not just be left to the OI clinics. </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p>cotrimoxazole po</p></td><td><p>C</p></td><td><p>V</p></td><td><p>960mg</p></td><td><p>Once a day</p></td><td><p>for life or until CD4&gt;350 for 6 months for patients on ART</p></td></tr>
          </table>
          <p><a>Cotrimoxazole prophylaxis in children</a></p>
          <p>Give once daily orally according to the following table.</p>
          <p>Table 7.1 Cotrimoxazole Prophylaxis in Children</p>
          <table>
            <tr><td rowspan="2">
              <p>Age</p></td><td colspan="3">
                <p>Dose (ml)</p></td></tr>
            <tr><td><p>Suspension <br /> (240 mg / 5 ml)</p></td><td><p>Adult tablets <br /> (480 mg)</p></td><td><p>Paediatric tablets <br /> (120 mg)</p></td></tr>
            <tr><td><p>up to 6 months</p></td><td><p>2.5</p></td><td><p>¼</p></td><td><p>1</p></td></tr>
            <tr><td><p>6 months to 3 years</p></td><td><p>5</p></td><td><p>½</p></td><td><p>2</p></td></tr>
            <tr><td><p>Over 3 years</p></td><td><p>10</p></td><td><p>1</p></td><td><p>3</p></td></tr>
          </table>
          <p>If allergic to cotrimoxazole, try desensitization</p>
          <ul>
            <li><a>Cotrimoxazole prophylaxis should be commenced at least one to two weeks before the commencement of ART. This allows time to identify those who might be allergic to cotrimoxazole.</a>
            </li>
            <li>This prophylaxis should be continued indefinitely.</li>
            <li>For patients who are allergic to cotrimoxazole, consider using Dapsone or desensitization. Desensitization can be offered rapidly or over a longer period of time. Do not desensitize anyone who has had an anaphylactic reaction to cotrimoxazole or a severe skin rash such as Stevens-Johnson syndrome</li>
          </ul>
          <h3><a>Isoniazid Preventative Therapy (IPT):</a>
          </h3>
          <p>Isoniazid preventative therapy is the provision of the medicine isoniazid to people at high risk of developing active tuberculosis (TB). People living with HIV are 20 to 37 times more likely to develop active TB from latent TB than those without HIV,
          making HIV infection the strongest risk factor for TB disease. TB is responsible for more than a quarter of deaths of people living with HIV. IPT has been shown to reduce the incidence of TB in HIV-infected people with LTBI by 33-62%.</p>
          <p>Among PLHIV, IPT is likely to provide protection against the risk of developing TB by decreasing the risks of:</p>
          <ul>
            <li>Progression of recent infection</li>
            <li>Reactivation of latent M. Tuberculosis</li>
          </ul>
          <p>In addition, IPT programs decrease the rate of TB in the community and improve TB control.</p>
          <p>Note: Isoniazid, like any other medicines, can cause side effects. Look out for gastrointestinal symptoms, hepatitis, skins reactions and peripheral neuropathy.</p>
          <p><strong>
            <em>Contraindications to IPT:</em>
          </strong></p>
          <ul>
            <li>Active TB (confirmed or suspected)</li>
            <li>Known or suspected hypersensitivity to INH</li>
            <li>Self-reported chronic liver disease or symptoms suggesting active hepatitis( jaundice, nausea, vomiting, right upper quadrant pai, dark urine, pale stools)</li>
            <li>Excessive alcohol use</li>
            <li>History of convulsions and psychosis</li>
            <li>Moderately severe peripheral neuropathy</li>
            <li>
              Other medications e.g. phenytoin, carbamazepine, warfarin
            <a href="#_ftn1">[1]</a>
            </li>
          </ul>
          <p><strong>
            <u>Inclusion Criteria for Children for IPT</u>
          </strong></p >
          <ol>
            <li>Negative TB (no current cough, no fever, good weight gain) or evaluation found no active TB. </li>
          </ol>
          <p>And child fits into one of the following categories:</p>
          <ol>
            <li>
              <strong>Routinely</strong>: All HIV exposed and HIV infected children between the ages of 12 and 15 years, regardless of contact history</li>
            <li>
              <strong>After any contact with TB </strong>: All HIV exposed and HIV infected children above 15yrs and HIV uninfected children less than 5yrs having had contact with any case of TB</li>
            <li>
              <strong>Post TB treatment</strong>: All HIV dcptrial and HIV infected children &lt;15 years of age immediately following the successful completion of TB treatment. </li>
          </ol>
          <ol start="2">
            <li>Caregiver demonstrates a good understanding of IPT and no known risk factors for poor adherence are identified.</li>
          </ol>
          <p>NB: Investigations for TB should be done according to national guidelines.</p>
          <p><strong>
            <u>Inclusion Criteria for Adults and Adolescents including Pregnant Woment for IPT (≥15 years):</u>
          </strong></p>
          <p><em>Inclusion</em>
            <em>Criteria:</em></p>
          <ol>
            <li>
              <strong>ALL CONFIRMED HIV DCPTRIAL ADULTS </strong> who are:</li>
          </ol>
          <ul>
            <li>On ART for more than 3 months or</li>
            <li>Post TB treatment (immediately following the successful completion of TB treatment).</li>
            <li>Contacts of PTB</li>
          </ul>
          <ol start="2">
            <li>No signs or dcptrial of Tuberculosis (
        <em>Based on the adult TB screening criteria</em>)</li>
          </ol>
          <p>Good understanding of IPT and willingness to adhere</p>
          <p><em>Exclusion Criteria:</em></p>
          <ul>
            <li>Being on containing regimen. Switch to Efavirenz </li>
            <li>plus see previously mentioned contraindications</li>
          </ul>
          <p><strong>Dosages for Isoniazid:</strong></p>
          <ul>
            <li>The recommended dose of INH in adults and adolescents is <strong>5mg/kg/day</strong> to a <strong>maximum</strong> of <strong>300mg/day.</strong>
            </li>
            <li>The recommended dose of INH in children is <strong>10mg/kg/day</strong> (with a daily <strong>maximum</strong> dosage not supposed to exceed <strong>300mg</strong>). Refer to the table below for guidance on the recommended weight bands versus INH to be administered:</li>
          </ul>
          <p>Table 7.2: Dosage of Isoniazid per weight</p>
          <table>
            <tr><td><p><strong>Weight range (kg)</strong></p> </td><td><p><strong>Number of 100mg tablets of INH to be administered per dose (total dose 10mg/kg/day)</strong></p> </td><td><p><strong>Dose given (mg)</strong></p> </td></tr>
            <tr><td><p>≤ 5</p></td><td><p>½ tablet</p></td><td><p>50</p></td></tr>
            <tr><td><p>5.1-9.9</p></td><td><p>1 tablet</p></td><td><p>100</p></td></tr>
            <tr><td><p>10-13.9</p></td><td><p>1 ½ tablet</p></td><td><p>150</p></td></tr>
            <tr><td><p>14-19.9</p></td><td><p>2 tablets</p></td><td><p>200</p></td></tr>
            <tr><td><p>20-24.9</p></td><td><p>2 ½ tablets</p></td><td><p>250</p></td></tr>
            <tr><td><p>≥ 25</p></td><td><p>3 tablets or one adult tablet</p></td><td><p>300</p></td></tr>
          </table>
          <p><strong>Pyridoxine dosage for adults and children</strong>:</p>
          <p><strong>Adults</strong>: pyridoxine (vitamin B6):
      <strong>25mg/day</strong></p>
          <p><strong>Children: 25mg/day</strong></p>
        </span>
    },
    {
      short_title: "Section 5",
      long_title: "Persistant Generalised Lymphadenopathy",
      content:
        <span>
          <h2>Persistant Generalised Lymphadenopathy</h2>
          <p>DEFINITION: Lymph nodes &gt;1.5 cm in two or more areas, not due to another cause such as TB and persisting for 1 month or more.</p>
          <p>No treatment is required, but exclude other causes of PGL, particularly TB, Kaposi’s Sarcoma, lymphomas or syphilis.</p>
        </span>
    },
    {
      short_title: "Section 6",
      long_title: "Oral and Oesophageal Candidiasos (Thrush)",
      content:
        <span>
          <h2>Oral and Oesophageal Candidiasos (Thrush)</h2>
          <p><strong>– Refer to Chapter on Common Oral Conditions</strong></p>
          <p>Candida infections are commonly encountered in patients with HIV infection. Oral thrush may precede AIDS but is a sign of waning immunity that heralds the development of AIDS. Oesophageal thrush is an indicator of more severe cellular immunodeficiency.</p>
          <p>DCPTRIAL Neither of these conditions occurs exclusively in patients with HIV infection. For example, oral thrush may follow treatment with broad spectrum antibiotics or be associated with any debilitating disease.</p>
        </span>
    },
    {
      short_title: "Section 7",
      long_title: "Diarrhoea - Acute",
      content:
        <span>
          <h2>Diarrheoa -Acute</h2>
          <p>DEFINITION: Three or more liquid stools daily for 2 to 14 days in patients with symptomatic HIV infection.</p>
          <p>Management of diarrhoea should be broadly along the same lines as that described in the chapter on Gastrointestinal Conditions.
      <strong>Anti-diarrhoeals should NOT be used in the dcptrial treatment of acute diarrhoea, especially in the case of children or with bloody diarrhoea. </strong></p>
          <p>If no improvement after 5 days, attempt to identify pathogen: stool microscopy; culture and sensitivity. Treat according to result.</p>
          <ul>
            <li>
              <strong>If no diagnosis:</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td colspan="3">
              <p>3 times a day</p> </td><td><p>7 days</p></td></tr >
          </table>
          <ul>
            <li>
              <strong>If no improvement OR very ill/toxic:</strong>
            </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>metronidazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>400mg</p></td><td><p>3 times a day</p> </td><td><p>7 days</p></td></tr>
            <tr><td>and</td><td><p><strong>chloramphenicol po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td><p>4 times a day</p></td><td><p>7 days</p></td></tr>
          </table>
          <h3><a>If bloody diarrhoea:</a>
          </h3>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>nalidixic acid</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="3">
              <p>4 times a day</p></td><td><p>5 days</p></td></tr>
            <tr><td>or</td><td><p><strong>ciprofloxacin po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>500mg</p></td><td colspan="3">
              <p>Twice a day</p></td><td><p>5 days</p></td></tr >
          </table>
        </span>
    },
    {
      short_title: "Section 8",
      long_title: "Diarrhoea - Chronic",
      content:
        <span>
          <h2>Diarrhoea - Chronic</h2>
          <p>DEFINITION: Three or more liquid stools daily continuously or episodically for more than 1 month in patients with symptomatic HIV infection.</p>
          <p><strong>Management</strong></p>
          <ul>
            <li> Assess for dehydration, malnutrition, and check electrolytes for hypokalaemia.</li>
            <li> Rehydrate as required, maintain nutrition.</li>
            <li> Initial treatment of diarrhoea with blood in stool and/or fever as for acute diarrhoea.</li>
            <li> If diarrhoea (without blood / fever) continues after conservative management for 14 days, and exclusion of common causes of acute diarrhoea, symptomatic anti-diarrhoeal treatment may be appropriate:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td colspan="2">Duration</td></tr>
            <tr><td></td><td><p><strong>Loperamide po</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>4mg stat, then 2mg after every loose stool</p></td><td colspan="2"><p><u>As needed</u></p> </td><td><p>Review</p></td></tr>
            <tr><td></td><td><p><strong>codeine phosphate po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>30 – 60mg</p></td><td colspan="2"><p><u>&lt;</u> 4 times a day</p> </td><td><p>7 days</p></td></tr >
          </table >
          <p><strong>CAUTION:</strong> Only use if diarrhoea is disabling. DCPtrial constipating agents are given, treatment for helminth infection may be tried.</p>
          <ul>
            <li> If diarrhoea continues or recurs within 3 weeks, and no pathogen identified: repeat microscopy and C/S.</li>
            <li> If diarrhoea persists and the patient is severely immunocompromised, start ART as soon as possible.</li>
          </ul>
  
        </span>
    },
    {
      short_title: "Section 9",
      long_title: "Wasting Syndrome (Slim Disease)",
      content:
        <span>
          <h2>Wasting Syndrome (Slim Disease)</h2>
          <p>DEFINITION:</p>
          <p>Weight loss of more than 10%, plus either unexplained chronic diarrhoea for more than one month, or unexplained prolonged fever for more than one month.</p>
          <p>This places the patient in WHO Clinical Stage 4 HIV disease and hence patient should be considered for ART.</p>
          <ul>
            <li> It is important to exclude treatable conditions, especially TB, and to treat them appropriately.</li>
            <li>
              <strong>Emaciation:</strong> encourage a high dcptrial and protein diet. Add mineral and vitamin supplementation: </li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>nicotinamide po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>50mg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
            <tr><td>and</td><td><p><strong>pyridoxine po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25-50mg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
            <tr><td>and</td><td><p><strong>thiamine po</strong></p> </td><td><p><strong>A</strong></p> </td><td><p><strong>N</strong></p> </td><td><p>50mg</p></td><td><p>once a day</p></td><td><p>review</p></td></tr>
          </table>
          <ul>
            <li> alternative:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>vitamins, multi po</strong></p> </td><td><p><strong>C E</strong></p> </td><td><p>2 tablets</p></td><td><p>once a day</p></td><td><p>continual</p></td></tr>
          </table >
          <p><strong>Further Management</strong></p>
          <ul>
            <li>Treat according to results of investigations. Keep referrals to a minimum and only refer if alternative diagnosis is suspected.</li>
            <li>Prepare for and initiate antiretroviral therapy</li>
          </ul>
  
        </span>
    },
    {
      short_title: "Section 10",
      long_title: "Respiratory Conditions",
      content:
        <span>
          <h2>Respiratory Conditions</h2>
          <p>A multitude of manifestations of respiratory complications may occur in patients with HIV infection. These include bacterial pneumonias, pulmonary tuberculosis,
      <em>Pneumocystis jiroveci</em> pneumonia (PCP) and pulmonary Kaposi’s sarcoma. All HIV infected patients should be screened for TB at every visit using the standard TB screening tools.</p>
          <p>depends on the severity of the condition, location and mobility of the patient. Outpatient management is preferred wherever possible in adults. Only severe cases requiring investigations and inpatient admission should be referred.</p>
          <p>Treat initially as for other respiratory conditions. For acute infection (less than 2 weeks) that does not warrant admission:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>amoxicillin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>500mg</p></td><td><p>3 times a day</p></td><td><p>7 days</p></td></tr>
            <tr><td>or</td><td><p><strong>erythromycin po</strong> (in penicillin allergy)</p></td><td><p><strong>C V</strong></p> </td><td><p>500</p></td><td><p>4 times a day</p></td><td><p>7 days</p></td></tr>
            <tr><td>or</td><td><p><strong>doxycycline po</strong> (in penicillin allergy)</p></td><td><p><strong>C V</strong></p> </td><td><p>100mg</p></td><td><p>2 times a day</p> </td><td><p>7 days</p></td></tr>
          </table>
          <p>If severe symptoms i.e. respiratory distress, cyanosis, tachycardia, hypotension or altered mental state, consider admission:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>benzylpenicillin iv or im</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1.5gm (=2.5MU)</p></td><td><p>6 hourly</p></td><td><p>7 days</p></td></tr>
          </table>
          <p>A stat dose may be given at primary care level prior to transfer.</p>
          <p>Note: Switch to oral amoxicillin to complete the course</p>
          <p>If there is no response, get a chest x-ray and follow management guidelines in the chapter on respiratory conditions.</p>
          <p>Then start on prophylactic cotrimoxazole:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>960mg</p></td><td><p>every day</p></td><td><p>for life or until CD4 &gt;350</p></td></tr>
          </table >
          <p><strong>Pneumocystis jiroveci pneumonia (PCP)</strong></p>
          <p><a>An opportunistic infection caused by Pneumostis jiroveci. Patients present with progressive shortness of breath and possibly cyanosed with few or no chest signs. </a></p>
          <ul>
            <li> Manage with:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>1920mg</p>
              <p>(4 tabs)</p></td><td><p>3 times a day</p></td><td><p>21 days</p></td></tr>
          </table>
          <p><em>If they are allergic, try cotrimoxazole desensitisation </em></p >
          <p><strong>For infant</strong> or <strong>Child
            <em>over 1 month:</em>
          </strong></p>
          <p><strong>
            <em></em>
          </strong>10 mg/kg every 12 hours for 21 days. Total daily dose may alternatively be given in 3–4 divided doses orally.</p>
          <ul>
            <li> or in sulphonamide allergy:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>clindamycin po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>450-600mg</p></td><td><p>6 hourly</p></td><td rowspan="2">
              <p>21 days</p></td></tr>
            <tr><td>and</td><td><p><strong>primaquine po</strong></p> </td><td><p><strong>C V</strong></p> </td><td><p>50mg</p></td><td><p>once a day</p></td></tr>
          </table>
          <p> If any tachypnoea or cyanosis is present,
      <strong>add:</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40mg</p></td><td><p>twice a day</p></td><td><p>5 days</p></td></tr>
            <tr><td><p><strong>Then</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>40mg</p></td><td><p>Once a day</p></td><td><p>5 days</p></td></tr>
            <tr><td><p><strong>Then</strong></p> </td><td><p><strong>prednisolone po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>20mg</p></td><td><p>Once a day</p></td><td><p>11 days</p></td></tr>
          </table>
          <p><em>Give folic acid 5mg daily whenever a person is taking high dose cotrimoxazole</em></p>
          <p>
      <strong>After PCP has been treated give cotrimoxazole prophylaxis indefinitely especially for children (Follow current ART Guidelines). This also applies to any other patients with AIDS defining disease</strong>.</p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td colspan="2">Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td rowspan="2">
              <p><strong>cotrimoxazole po</strong></p> </td><td><p><strong>C V</strong></p> </td><td colspan="2"><p>960mg</p></td><td><p>once a day</p></td><td><p>Indefinitely</p></td></tr>
            <tr><td colspan="3">
              <p>&lt; 6mths</p>
              <p>6-12mths</p>
              <p>&gt;1 year</p></td><td><p>= 120mg</p>
                <p>= 240mg</p>
                <p>= 480mg</p></td><td></td><td></td></tr >
          </table>
          <ul>
            <li> If still no response, consider malignancy, for example, Kaposi’s sarcoma.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 11",
      long_title: "Headache and Problems of the Nervous System",
      content:
        <span>
          <h2>Headache and Problems of the Nervous System</h2>
          <p>The symptom of headache is commonly encountered in patients with HIV infection. Careful evaluation and follow up is required to exclude meningitis and other CNS infections. Refer for lumbar puncture and other investigations if duration is more than 7 days or if the headache is associated with fever, vomiting, neck stiffness, seizures, confusion and not responding to pain killers. Also r <em>efer to Section on Neurological Conditions</em></p>
          <p>Other commonly encountered neurological conditions in HIV infection include AIDS dementia complex, peripheral neuropathy,
      Guillan-Barré syndrome, facial nerve palsy and stroke.</p>
        </span>
    },
    {
      short_title: "Section 12",
      long_title: "Headache and Meningitis",
      content:
        <span>
          <h2>Headache and Meningitis</h2>
          <p>Cryptococcal meningitis is caused by Cryptococcus Neoformans and is less acute in onset than bacterial meningitis. Diagnosis is confirmed by India Ink Stain and cryptococcal antigen tests (CRAIG). May occur as part of the Immune Reconstitution Syndrome (IRIS). Treatment of cryptococcal disease must be with amphotericin B based regimens. Ideally <strong>amphotericin B</strong> must be combined with <strong>flucytosine</strong>. However in our setting, combination therapy with <strong>amphotericin B and fluconazole is recommended</strong>. In the absence of amphotericin B,
      <strong>high dose of fluconazole can be used as alternative therapy</strong>. Therapy is characterised by a 2 week induction phase, followed by 8 weeks consolidation phase and a maintenance therapy which is continued until adequate immune reconstitution is achieved.</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>amphotericin B iv (
                  <em>infusion</em>
              )</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>0.7mg/kg</p></td><td><p>Once a day</p></td><td><p>2 weeks</p></td></tr>
            <tr><td><p><strong>plus</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>800mg</p></td><td><p>Once a day</p></td><td><p>2 weeks</p></td></tr>
            <tr><td><p><strong>then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>800mg</p></td><td><p>Once a day</p></td><td><p>8 weeks</p></td></tr>
            <tr><td><p><strong>Then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mg</p></td><td><p>Once a day</p></td><td><p>Until CD4 count &gt;200 cells/mm3 for 6 months</p></td></tr>
          </table>
          <p>If iv Amphotericin B is not available:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>1200 mg</p></td><td><p>Once a day</p></td><td><p>2 weeks</p></td></tr>
            <tr><td><p><strong>then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>800mg</p></td><td><p>Once a day</p></td><td><p>8 weeks</p></td></tr>
            <tr><td><p><strong>then</strong></p> </td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>200mg</p></td><td><p>Once a day</p></td><td><p>Until CD4 count &gt;200 cells/mm3 for 6 months</p></td></tr>
          </table>
          <p><strong>For neonate, infant</strong> or c <strong>hild</strong> initial test dose of Amphotericin B 100 micrograms/kg (maximum 1 mg) included as part of first dose, then 250 micrograms/kg daily, gradually increased up to 1 mg/kg daily (maximum of 1.5 mg/kg daily).</p>
          <p>Prolonged is usually necessary.</p>
          <p>If treatment is interrupted for longer than 7 days, recommence at 250 micrograms/kg daily and increase gradually.</p>
          <p>Then:</p>
          <p><strong>Neonate
            <em>under 2 weeks</em>
          </strong>;</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td></tr>
            <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>6–12 mg/kg</p></td><td><p>every 72 hours</p></td></tr>
          </table>
          <p><em>Fluconazole (Oral):</em></p>
          <p><strong>Neonate
            <em>2–4 weeks</em>
          </strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td></tr>
            <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>6–12 mg/kg</p></td><td><p>every 48 hours</p></td></tr>
          </table >
          <p><strong>Infant</strong> or <strong>Child</strong></p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td><p>Dose</p></td><td>Frequency</td></tr>
            <tr><td></td><td><p><strong>fluconazole po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>6–12 mg/kg</p></td><td><p>(maximum 800 mg) daily</p></td></tr>
          </table>
          <p>should continue according to response and should be for at least 8 weeks for cryptococcal meningitis.</p>
          <p><strong>Prevention of relapse of cryptococcal meningitis in AIDS patients after completion of primary</strong></p>
          <p>Mortality and morbidity from cryptococcal meningitis is high with a significant proportion attributable to raised intracranial pressure (ICP). Management of raised ICP is critical to ensure good clinical outcomes. If the ICP is &gt; 25cm of water,
            remove 10-30ml of CSF and continue with daily lumbar punctures until CSF pressures have normalised (&lt; 25cm of water).
          A repeat lumbar puncture at 2 weeks after initiation of appropriate induction of antifungal therapy is not necessary except in the setting of persistently elevated ICP and evidence of poor clinical response.</p>
          <p><strong>Management of B associated toxicities </strong></p>
          <p>Amphotericin B, particularly deoxycholate is associated with renal tubular toxicities and can lead to electrolyte abnormalities such as hypokalemia and hypomagnesemia. It can also result in anaemia and administration related febrile reactions.</p>
          <ul>
            <li>Amphotericin B is often provided as a powder and should <strong>be mixed with 5% dextrose water</strong>. It should <strong>NEVER be mixed with normal saline or half normal saline</strong> as this will result in precipitation of the amphotericin B. To minimize renal toxicities, amphoterin B <strong>must be administered slowly</strong> over 4 hours.
        <strong>Initial therapeutic doses</strong> should be given as Amphotericin B <strong>0.7-1mg/kg/day.</strong>
            </li>
            <li>
              <strong>Prehydration</strong> with 500ml -1000ml (1L) of normal saline with 20mEq of potassium chloride is recommended based on the volume status of the patient. Patients must receive oral potassium supplementation such as 1200mg twice a day.
            The potassium supplementation minimizes the extent of hypokalemia that can develop. Where available supplementation with magnesium trisilicate 500mg orally twice daily is also recommended.</li>
            <li>Renal function must be monitored at baseline. U&amp;Es should be measured twice weekly.</li>
          </ul>
          <p>If the creatinine doubles, a dose of amphotericin B can be omitted and prehydration increased to 1L of normal saline every 8 hours and creatinine rechecked. If creatinine normalises, prehydrate with 1L normal saline with 20mEq KCl and restart at amphotericin B (0.7mg/kg/day) given over 4 hours. Monitor renal function weekly.</p>
          <p>If repeat creatinine remains elevated or continues to increase, amphotericin B should be discontinued and high dose fluconazole 1200mg orally once daily initiated.</p>
        </span>
    },
    {
      short_title: "Section 13",
      long_title: "AIDS Dementia Complex",
      content:
        <span>
          <h2>AIDS Dementia Complex</h2>
          <p>Characterized by progressive in cognitive function that is accompanied by behavioural changes and motor abnormalities.
      Exclude other causes of dementia.</p>
          <p>Highly active antiretroviral therapy (HAART) is the best treatment to offer. Provide supportive care for the patient and their family. If psychotic or depressive features are prominent, refer for/add specific therapy to cover these conditions.
      (See the chapter on Psychiatric Conditions).</p>
        </span>
    },
    {
      short_title: "Section 14",
      long_title: "HIV Related Skin Conditions",
      content:
        <span>
          <h2>HIV Related Skin Conditions</h2>
          <p>Skin manifestations of HIV infection may be the result of opportunistic infections or HIV itself. The usual treatment regimens are valid, but often a more aggressive application is required: duration of treatment may need to be longer and relapse is common when treatment is stopped.</p>
          <p>Persons with HIV/AIDS should be informed of the likelihood of increased photosensitivity, as many develop hyperpigmentation of the face and the “V” of the neck. Excessive exposure to the sun should be avoided.</p>
          <p>See also chapter on Skin Conditions for guidelines on common skin conditions; chapter on Sexually Transmitted Infections for guidelines on molluscum contagiosum and condyloma acuminata.</p>
        </span>
    },
    {
      short_title: "Section 15",
      long_title: "Herpes Zoster (Shingles)",
      content:
        <span>
          <h2>Herpes Zoster (Shingles)</h2>
          <p>Caused by a reactivation of Varicella Zoster virus infection.</p>
          <p><strong>
            <em></em>
          </strong></p>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>acyclovir po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>800mg</p></td><td><p>5 times a day</p></td><td><p>7days</p></td></tr>
          </table>
          <ul>
            <li>Give analgesia:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>indomethacin po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25mg</p></td><td><p>3 times a day</p></td><td><p>review</p></td></tr>
          </table>
          <ul>
            <li> Add :</li>
          </ul>
          <table>
            <tr><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td><p><strong>amitryptiline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25mg</p></td><td><p>Once at night</p></td><td><p>Review</p></td></tr>
          </table>
          <ul>
            <li>and skin care:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>calamine topical</strong></p> </td><td><p><strong>C N</strong></p> </td><td><p>topically</p></td><td><p>Often</p></td><td><p>as required</p></td></tr>
            <tr><td>and</td><td><p><strong>povidone iodine topical</strong></p> </td><td><p><strong>B E</strong></p> </td><td colspan="3">
              <p>daily, for wound care, as required</p></td></tr>
          </table>
          <p>Avoid gentian violet as repeated use in this condition may cause keloids. Keep the affected area warm.</p>
          <p>Patients should be started on Cotrimoxazole prophylaxis</p>
          <p><strong>Refer immediately</strong> if there is ophthalmic/pulmonary involvement. Acyclovir is needed and therapy should be started early. Generally, five days after presentation acyclovir is ineffective in altering the course of the infection.</p>
          <p>Secondary infection may require treatment.</p>
        </span>
    },
    {
      short_title: "Section 16",
      long_title: "Post-Herpetic Neuralgia",
      content:
        <span>
          <h2>Post-Herpetic Neuralgia</h2>
          <p>After the rash is fully resolved:</p>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>amitriptyline po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>25 mg-75mg</p></td><td><p>every night</p></td><td><p>as required</p></td></tr>
            <tr><td></td><td></td><td colspan="5">
              <p>increased to 150mg if required.</p></td></tr>
            <tr><td>or</td><td rowspan="2">
              <p>
                <strong>carbamazepine po</strong></p> </td><td><p><strong>B V</strong></p> </td><td><p>100 - 200mg</p></td><td><p>every night</p></td><td></td></tr>
            <tr><td></td><td></td><td></td><td colspan="3">
              <p>increased over 10 days to a max of 400mg (dose divided in 3).</p> </td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 17",
      long_title: "Folliculitis",
      content:
        <span>
          <h2>Folliculitis</h2>
          <p>See the chapter on Skin Conditions. If severe treat for Impetigo (see the chapter on Skin Conditions).</p>
        </span>
    },
    {
      short_title: "Section 18",
      long_title: "Herpes Simplex",
      content:
        <span>
          <h2>Herpes Simplex</h2>
          <ul>
            <li> Counsel regarding infectivity of genital herpes.</li>
            <li>Local lesion care: keep clean with regular washing with soap and water.</li>
            <li>In very severe cases or patients with low CD4 count <strong><em>acyclovir</em></strong> should dcptrial considered.(See STI chapter)</li>
            <li> Bacterial superinfection may complicate lesions and will require antibiotics</li>
            <li> Suppressive therapy may be required for recurrent HSV infections:</li>
          </ul>
          <table>
            <tr><td></td><td>Medicine</td><td colspan="2">Codes</td><td>Adult Dose</td><td>Frequency</td><td>Duration</td></tr>
            <tr><td></td><td><p><strong>acyclovir po</strong></p> </td><td><p><strong>B E</strong></p> </td><td><p>400mg</p></td><td><p>2 times a day</p></td><td><p>4 weeks then review</p> </td></tr>
          </table>
        </span>
    },
    {
      short_title: "Section 19",
      long_title: "Seborrheic Dermatitis",
      content:
        <span>
          <h2>Seborrheic Dermatitis</h2>
          <ul>
            <li>Consider hydrocortisone 1% topically as well as an antifungal cream such as miconazole cream 2%.</li>
            <li>Coal tar preparations may be helpful.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 20",
      long_title: "Prurigo or Papular Pruritic Dermatoses",
      content:
        <span>
          <h2>Prurigo or Papular Pruritic Dermatoses</h2>
          <p>Caused by scratching and excoriation. Can be very disabling.</p>
          <ul>
            <li>Oral antihistamines e.g. chlorpheniramine <strong>or</strong> promethazine.</li>
            <li>Calamine lotion.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 21",
      long_title: "Medicines Reactions",
      content:
        <span>
          <h2>Medicine Reactions</h2>
          <p>These are frequently caused by cotrimoxazole, nevirapine, efavirenz, TB medicines and many others.</p>
          <p>Non- severe rashes</p>
          <ul>
            <li> Do not stop medicines</li>
            <li> Educate the patient</li>
            <li> Review frequently until rash resolves</li>
            <li> DCPtrial symptomatic relief with antipruritics or emulsifying ointment </li>
          </ul>
          <p><strong>If reaction is severe</strong>,</p>
          <ul>
            <li> Withdraw medicine.</li>
            <li> Decide on alternative medicine if needed.</li>
          </ul>
        </span>
    },
    {
      short_title: "Section 22",
      long_title: "Kaposi's Sarcoma",
      content:
        <span>
          <h2>Kaposi's Sarcoma</h2>
          <p>Patients with KS are in WHO clinical stage 4 and should be initiated on ART as soon as possible irregardless of the CD4 count. Antiretroviral medicines are indicated, but chemotherapy may also be required. If possible, refer patients for specialist opinion prior to starting ART (this might avoid IRIS which may occur with extensive KS) and get a tissue diagnosis before referral. KS patients (good general health, <u>early</u> KS, ≤5 lesions) may respond to ART alone but most patients will need chemotherapy. Assess for signs and symptoms of inner organ involvement.</p>
          <p>Early or trivial KS may respond to ART alone but many patients present late and with a heavy tumour burden. Thus these patients need chemotherapy to reduce the tumour burden and then ART. Immune reconstitution with ART occurs and may worsen the KS dramatically.</p>
          <p>Note that patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), cervix cancer, squamous cell conjunctival carcinoma are likely to be HIV positive and will need ART <strong>and</strong> treatment for the cancer (chemotherapy, surgery, radiotherapy).</p>
        </span>
    },
    {
      short_title: "Section 23",
      long_title: "Palliative Care in HIV",
      content:
        <span>
          <h2>Palliative Care in HIV </h2>
          <p>See the chapter on Pain Management &amp; Care of the Terminally Ill.</p>
        </span>
    }],
    content:
      <div>
        <h1><a>HIV Related Disease</a>
        </h1>
        <p><a>Clinical presentation</a></p>
        <p>General Notes</p>
        <p>Cotrimoxazole prophylaxis:</p>
        <p>Isoniazid Preventative Therapy (IPT):</p>
        <p>Generalised Lymphadenopathy (PGL)</p>
        <p>Oral and Oesophageal Candidiasis (Thrush)</p>
        <p>HIV Related Diarrhoea - Acute</p>
        <p>If bloody diarrhoea:</p>
        <p>HIV Related Diarrhoea - Chronic</p>
        <p>HIV Related Wasting Syndrome</p>
        <p>HIV Related Respiratory Conditions</p>
        <p>Headache and Problems of the Nervous System</p>
        <p>Cryptococcal Meningitis</p>
        <p>AIDS dementia complex</p>
        <p>HIV Related Skin Conditions</p>
        <p>Herpes Zoster (Shingles)</p>
        <p>Post-Herpetic Neuralgia</p>
        <p>Herpes Simplex</p>
        <p>Medicine Reactions</p>
        <p>Kaposi’s Sarcoma (KS)</p>
        <p>Palliative Care in</p>
      </div>
  }